This site is intended for healthcare professionals
Drug news

FDA Advisory Committee rejects Melblez Kit (Delcath) for Ocular melanioma metastatic to the Liver

Read time: 1 mins
Last updated:6th May 2013
Published:6th May 2013
Source: Pharmawand

Delcath Systems, Inc. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) voted 16 to 0 with no abstentions that benefits of treatment with Delcath's Melblez Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System) for the treatment of patients with unresectable Ocular melanoma metastatic to the Liver do not outweigh the risks associated with the procedure.

Outside of the United States, the proprietary product to deliver and filter melphalan hydrochloride is marketed under the trade name Delcath Hepatic ChemosatDelivery System (Chemosat Delivery System for Melphalan.) The Company obtained authorization to affix a CE Mark for the Generation Two Chemosat Delivery System for Melphalan in April 2012.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights